This review critically examines the evolution of treatment strategies for HER2-positive mBC, focusing on first-line treatment selection, maintenance, CNS management, post-T-DXd sequencing, long responders, mechanisms of resistance and biomarker development.
M. Palleschi, A. Viansone, Filippo Merloni et al.· Cancer Treatment Reviews· 0 citations
Background/objectives Transdermal fentanyl (TDF) is widely used for moderate-to-severe cancer pain, yet substantial variability in fentanyl exposure, analgesic response, and tolerability remains incompletely explained by clinical factors. We evaluated whether pharmacogenetic variability is associated with pharmacokinet...
Lucia Angelini, I. Azzali, A. Carlini et al.· Frontiers in Pain Research· 0 citations
Age at diagnosis, disease stage, and surgical resection status were independently associated with OS, with stage emerging as the strongest determinant in HNPGLs.
A. Carlini, Mirea Berti, G. Lamberti et al.· Annals of Otology, Rhinology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
